Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
February 25, 2021
Earnings Call Speaker Segments
Holly Manning
executiveOperator, thank you. Good morning, everyone, and hello. We're glad you could be part of Agios' conference call for the fourth quarter of 2020. You can access the slides for today's call in the Investors section on agios.com, our website. Joining me now to provide prepared remarks are our Chief Executive Officer, Dr. Jackie Fouse; Dr. Chris Bowden, who serves as Chief Medical Officer; Darrin Miles, our Chief Commercial Officer; and Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs. Our Chief Scientific Officer, Dr. Bruce Car, will be with us for the Q&A portion. Before we get started, I'd like to remind all of you that some of what we say today will consist of forward-looking statements. Real outcomes may end up being materially different from what any forward-looking statements express or suggest, and that can happen because of assorted risks, uncertainties, and additional factors — among them the ones laid out in our latest SEC filings along with any later filings we might submit to the SEC. On that note, I'll turn things over to Jackie.
Jacqualyn Fouse
executiveThank you, Holly. Good morning to all of you, and I appreciate you being on the line for our call covering results from the fourth quarter of 2020. Before we dive into the thrilling work awaiting us in 2021, I'd like to pause and look back at the year that just passed, recognizing the remarkable difficulties that everyone at Agios, the patients we serve, and the worldwide community have confronted. Twelve months ago, when I delivered remarks on our Q4 2019 call, none of us could have predicted that merely a few weeks afterward, the COVID-19 outbreak would grow into a worldwide pandemic, closing our offices and bringing normal life to a standstill. A large number of our staff members, while working from home, had to juggle fresh demands in their personal lives — things like online schooling, caring for small children, and added anxiety regarding health and safety during a pandemic. Meanwhile, patients across the globe, among them participants in clinical trials, dealt with diminished ability to travel and reach medical centers. Simultaneously, the U.S. experienced considerable civil and political turmoil that laid bare even more clearly the racial and social divisions present in our nation. Amid these difficulties, the kindness, resolve, and spirit shown by the Agios team in backing one another, our patients, and our communities has left me deeply moved. As of last week, our cross-functional coronavirus task force marked the completion of its first year, having handled close to 750 inquiries from patients or health care providers spanning dozens of countries. For every single request, the team labors unrelentingly to lower the danger to patients and/or ease the strain on health care systems stemming from COVID-19, and went to tremendous lengths to make sure patients retained access to our medicines in spite of these unprecedented circumstances. Our facilities and HR teams have surpassed what duty requires in keeping our labs and offices safe for employees who must be present on site, which includes offering access to testing and contact tracing. For those working from home, they've put together personal and professional resources such as webinars about avoiding burnout, access to educational materials and activities for our children, virtual employee interactions to maintain our connections, and continuing team building activities to adapt our culture during this period and going forward. At the community level, we spearheaded a diversity initiative at Agios featuring speakers and workshops on valuing differences to sharpen our awareness and help us learn together. As the photos on Slide 5 show, we keep supporting causes that matter to us via fundraisers and events. And in December, our employees gave gifts to families with children battling life-threatening diseases; even with the realities and struggles of 2020 persisting into 2021, I still find myself tremendously hopeful about what lies ahead and more confident than ever in our capacity to overcome whatever comes our way. Looking at things through a business lens, there is plenty to feel enthusiastic about as we begin the next phase at Agios, now centered entirely on genetically defined diseases. Back in December, we shared our revised strategy along with the plan to divest our oncology assets to Servier, a thriving global pharma company focused on patients that has shown a strong dedication to growing its developing oncology portfolio. Under this deal, which goes before shareholders for a vote on March 25, Agios stands to gain cash consideration reaching as much as $2 billion, comprising $1.8 billion paid upfront and $200 million as a possible future milestone payment in cash, plus royalties of 5% on U.S. net sales of TIBSOVO starting at transaction close until loss of exclusivity, and royalties of 15% on U.S. net sales of vorasidenib from the first commercial sale until loss of exclusivity. Once $1.2 billion is returned to shareholders, the remaining proceeds will be kept to finance the company through key value-driving catalysts all the way to profitability, with no need for any further equity raises. Through these choices, the oncology portfolio can expand and prosper under Servier, while Agios gains the capital needed to fully realize the promise of potential treatments for genetically defined diseases, which in the end delivers the largest possible positive effect for patients. You can find further information in our press release, investor presentation and proxy statement, all available on our website at agios.com. During recent months, we have achieved important progress with mitapivat, our most advanced medicine, across our 3 initial therapeutic areas of focus, and that momentum positions us for a year full of catalysts, which Chris will discuss shortly. Beyond that, we are advancing additional genetically defined disease programs through our clinical and research pipelines; meanwhile, on the oncology side, we have kept delivering on both clinical and commercial efforts. We wrapped up the second full year of TIBSOVO net revenue at $121 million, surpassing our target of $115 million in net revenue. As we look toward how our commercial business will evolve, I am happy to share that Darrin Miles has been elevated to Chief Commercial Officer. Since coming aboard in 2015, he has held many positions at Agios, most recently serving as Senior Vice President of U.S. Commercial and Global Marketing. Darrin has performed exceptionally well in guiding our team toward outstanding TIBSOVO commercial results, while simultaneously getting us ready for our first genetically defined disease launch with PK deficiency in 2022. Darrin's considerate and authentic approach to leadership is apparent across our entire company. We hold great optimism regarding our promising future and our capacity to keep delivering transformative therapies to more patients than ever, thanks to our renewed focus and financial strength. With that, Chris, I will hand things over to you.
Chris Bowden
executiveThanks, Jackie. When I reflect on 2020, the commitment and ingenuity shown by our clinical teams—across both oncology and genetically defined disease areas—leave me deeply humbled. They pushed our clinical programs forward beyond what anyone expected for patients, all while navigating the difficulties brought on by the pandemic. Now, as 2021 begins, our excitement about the future in genetically defined diseases is high, and there's considerable work in front of us as we move our late-stage programs ahead and settle on choices regarding our next wave of research. I'll start by discussing mitapivat, the program we've taken furthest in diseases with a genetic cause. It's a first-in-class PKR activator, and right now we're studying it in three separate chronic hemolytic anemias: pyruvate kinase deficiency, thalassemia, and sickle cell disease. On the pyruvate kinase deficiency front, we recently reported top line data from the Phase III ACTIVATE and ACTIVATE-T trials. Those studies looked at mitapivat in adults with pyruvate kinase deficiency — the first in people who weren't getting regular transfusions, the second in people who were. In ACTIVATE, 40% of patients on mitapivat hit the primary endpoint, a sustained rise in hemoglobin, compared with 0 placebo patients — a highly statistically significant finding. In ACTIVATE, every key secondary endpoint that had been prespecified also reached statistical significance, demonstrating improvement over placebo. That includes in-patient reported outcomes based on changes from baseline, along with the pyruvate kinase deficiency diary score and the pyruvate kinase deficiency impact assessment score at week 24. We believe these results will strengthen our submission for regulatory approval and support our discussions with access providers. In ACTIVATE-T, more than 1/3 of patients experienced a meaningful reduction in transfusion burden, and 22% required no transfusions at all during the 24-week fixed-dose period. For both trials, the safety profile was consistent with data previously reported in PK deficiency patients. Results from both trials, including the PRO data, will be sent in for presentation at the European Hematology Association Virtual Conference, which runs from June 9 to the 17 this year. These findings strengthen the case that mitapivat may turn out to be the first therapy that modifies the disease course in pyruvate kinase deficiency, and they will underpin our worldwide regulatory submission, already in progress. Our plan is to seek approval in the U.S. sometime in the second quarter of 2021 and in the EU no later than mid-2021, with a commercial launch possibly arriving in 2022 across both regions. Now, on the Phase II mitapivat study in thalassemia: 20 patients were enrolled before enrollment wrapped up last year. Later, during June, fresh findings from 13 patients who could be assessed for efficacy were shared at the virtual EHA conference. Those findings showed that among 12 out of 13 evaluable individuals, mitapivat led to a hemoglobin increase of at least 1 gram per deciliter from week 4 through week 12. That count encompassed all 4 alpha thalassemia patients—a population that had lacked novel therapeutic choices for many decades. On top of that, 7 out of 8 beta-thalassemia patients maintained a hemoglobin response from week 12 all the way to week 24. By November 2020, the trial's extension phase still had 17 patients taking part. We're planning to send in the full data set covering all 20 patients from this study's core period so it can be presented at EHA. Back in December, we shared a first glimpse of our two worldwide pivotal trials of mitapivat in thalassemia, which are ENERGIZE and ENERGIZE-T. On Slide 11, up at the top, you can see that ENERGIZE is going to evaluate 171 patients who've been randomized 2:1 to either 100 milligrams of mitapivat BID or placebo, and these are beta and alpha thalassemia patients who don't receive regular transfusions. When it comes to the primary endpoint, it's the proportion of patients whose mean hemoglobin rises by at least 1 gram per deciliter compared with baseline across a 24-week core period. In ENERGIZE-T, 240 patients will be evaluated after being assigned randomly in a 2:1 ratio to receive either mitapivat at 100 milligrams twice daily or a placebo. Those enrolled have beta and alpha thalassemia and receive regular transfusions, which means they had between 6 and 20 red blood cell units transfused in the 24 weeks before randomization. The main goal is the proportion of patients achieving a 50% decrease in transfusion burden across any rolling 12-week window within the 48-week core period. Both studies are presently being made operational, and we anticipate launching these trials before the year concludes. Let's now discuss sickle cell disease. In the prior year, mitapivat became the initial PKR activator to show proof-of-concept for this condition, drawing on early findings from a study run in partnership with Dr. We have Swee Lay Thein from the National Institutes of Health. On Slide 12, you'll see that back in December at ASH, the NIH shared fresh results covering 11 patients. Those findings showed how mitapivat helped improve hemoglobin, and along with that came better hemolysis markers. Dr. Thein is still signing up patients for the core study, plus an extension study, and she's looking to share an update at a medical meeting sometime this year. On top of that, our partners at the University of Utrecht kicked off an investigator-sponsored trial of mitapivat for sickle cell disease at the end of last year, and they're also aiming to submit data from that study for a presentation at a medical meeting this year. Alongside those clinical efforts, we wrapped up sessions with regulators in the U.S. and the EU, aimed at moving our sickle cell disease program forward into pivotal development. What they told us shaped a pivotal development strategy that is both solid and carefully considered, and I'm glad to walk you through it now. Our view is that this plan lowers the risk on the approval pathway for mitapivat in this difficult disease and raises the odds of securing a broad indication on the label in 2026. The guidance from FDA and EMA regarding how the pivotal trial for mitapivat in sickle cell disease should be designed rested on data available at present, the design we originally put forward for the clinical trial, and the shifting treatment landscape. To be specific, the feedback we got was that in sickle cell disease, hemoglobin by itself isn't viewed as a validated surrogate for clinical benefit. Getting an accelerated approval based on an interim hemoglobin analysis is very unlikely, and unblinding at the interim could put the sickle cell pain crisis endpoint at risk. Because sickle cell disease is far more complex than other hemolytic anemias, the guidance we were given was unambiguous: collect data at 2 dose levels so that the pharmacodynamics and safety profile in this condition can be characterized more thoroughly. Based on that feedback, we designed the operationally seamless Phase II/III trial of mitapivat in adults living with sickle cell disease, which is the trial shown on Slide 13. The study will include people who are 16 or older, have had between 2 and 10 sickle cell crises in the last 12 months, and have hemoglobin levels of at least 5 and 5.5 while remaining under 10.5 grams per deciliter at screening. Patients currently taking voxelotor, crizanlizumab, or any other treatment designed to increase hemoglobin oxygen affinity cannot take part. Hydroxyurea use is allowed. In the Phase II part on your left, 69 patients were assigned in a 1:1:1 ratio to receive either 50 milligrams of mitapivat twice daily, 100 milligrams of mitapivat twice daily, or a matching placebo. The main goal we're measuring is how hemoglobin responds—specifically, whether there's a shift of 1 gram per deciliter or more from where patients started compared with week 12. Those results are what we'll use to lock in a well-defined dosing approach for the Phase III stage.
Chris Bowden
executiveThen, following the Phase II analysis, the Phase III trial on the right will enroll 198 patients and assign them in a 2:1 ratio to either the selected Phase II dose of mitapivat or a matched placebo. There will be 2 primary goals for this study: hemoglobin response, which is defined as a change of at least 1 gram per deciliter from baseline to week 52, and the annualized rate of sickle cell pain crises. We remain on schedule to launch the trial before the year is out. Because of these adjustments to our original pivotal strategy for mitapivat in sickle cell disease, our expectation now is regulatory approval in the 2026 time frame, rather than the approval at the end of 2025 that we previously guided toward. Our belief is that by resolving the feedback from the FDA and EMA ahead of starting the Phase II/III trial, this updated plan raises the probability of a broad competitive label that includes both hemoglobin and sickle cell pain crises endpoints when we launch. Here on Slide 14, you can see the strong pipeline we are assembling with mitapivat across these 3 initial indications. Just as we did with TIBSOVO, we are focused on moving mitapivat as rapidly as possible from pivotal development to regulatory approval. Beginning with pyruvate kinase deficiency next year, we see an opportunity to significantly broaden the labeled indications for mitapivat over the next 5 years, targeting 3 serious hemolytic anemias that urgently require new treatment options. In addition to mitapivat, we are moving our next-generation PKR activator, AG-946, through a Phase I healthy volunteer study. Enrollment in that trial started last fall, and by the end of the year we expect to submit data from the single ascending dose and multiple ascending dose cohorts for presentation at a medical meeting. According to our analysis, the totality of the AG-946 healthy volunteer data will guide the next steps for clinical development of this molecule. Bruce's team has worked diligently to generate a robust and promising research pipeline within the PK activation mechanism, and by the end of the year we intend to make decisions on the next wave of indications for these as well as our clinical stage drugs. We also have substantial non-pyruvate kinase opportunities in our research pipeline, among them a stabilizer of the enzyme deficient in phenylketonuria that degrades phenylalanine, and a unique approach to treating immuno acidemias and aciderias associated with inborn errors of metabolism. Our deep expertise built around cellular metabolism to elucidate cancer cell biology has been exploited to great effect in understanding multiple genetically defined conditions and has enabled us to build a deep portfolio of genetically defined targets. We look forward to sharing more about these programs at an R&D Day in the second half of the year. On Slide 16, we've outlined all of our 2021 key milestones. I'd like to shift attention now to our oncology efforts, since we've been working diligently and achieving meaningful headway on multiple late-stage programs spanning malignant hematology as well as solid tumors. At the ASCO-GI conference held last month, we presented a complete evaluation of the final results from the global Phase III ClarIDHy study of TIBSOVO involving patients whose IDH1-mutant cholangiocarcinoma had been treated previously. According to that final evaluation, patients assigned at random to receive TIBSOVO had a median overall survival of 10.3 months, whereas those randomized to placebo had 7.5 months. The hazard ratio for overall survival failed to achieve statistical significance. That said, a substantial share of those in the placebo group—70.5%—went on to receive TIBSOVO after crossover. A pre-specified analysis accounting for crossover revealed a median overall survival of 5.1 months among patients in the placebo arm, and the overall survival hazard ratio was found to be statistically significant. The safety profile seen during the trial matched what had been published before. Furthermore, we shared positive progression-free survival results last year that carried strong statistical significance. With this evidence in hand, we remain on schedule to file a supplemental new drug application for TIBSOVO in previously treated IDH1-mutant cholangiocarcinoma during the first quarter of 2021. Beyond cholangiocarcinoma, we are investigating whether IDH inhibition might help in low-grade glioma through our Phase III INDIGO study of vorasidenib. This agent, our dual IDH1/2 inhibitor capable of penetrating the brain, could potentially serve the approximately 80% of low-grade glioma patients who carry an IDH mutation. Despite the pandemic, enrollment has exceeded what we anticipated, which speaks to physicians' enthusiasm about what vorasidenib might offer in this study; and lastly, the Phase I dose escalation combination cohorts for AG-270 paired with taxanes are still bringing in patients. Turning to blood cancers, we continue enrolling participants in our Phase III frontline AML combination trials of TIBSOVO, along with our MDS expansion, and the AGILE MDS cohort should finish enrolling by the close of the year. Having said that, I'll hand things over to Darrin so he can cover our commercial results for the fourth quarter.
Darrin Miles
executiveThanks, Chris. Even with COVID-19 flaring up again during Q4 and ongoing restrictions on promoting products face-to-face, our team still achieved TIBSOVO net sales totaling $39.1 million for Q4 — that's 23% higher than what we saw in the third quarter. This lifts full-year 2020 net sales to $121 million, which represents a 102% year-over-year gain, and it topped the top end of the updated guidance we provided by $6 million. The quarter's results came from expansion in new prescriptions and refills along with favorable gross to net; we keep witnessing double-digit expansion across both academic and community settings, fueled by a 15% rise in new prescribers compared with Q3. Doctors' preference for TIBSOVO when treating frontline-intensive chemo-ineligible patients and those in the first relapsed setting stays robust, as do every leading indicator of how physicians perceive it, among them the widespread view that TIBSOVO constitutes the standard of care for patients who are newly diagnosed or relapsed/refractory with IDH1 mutations. Although our promotional activities remain confined to FDA-approved indications for TIBSOVO, we nonetheless see that roughly 50% of TIBSOVO usage in each setting occurs in combination, most often alongside an HMA; we've additionally noted ongoing expansion in TIBSOVO use among cholangiocarcinoma patients. Visibility into how far that usage extends is restricted to just one-third of the volume flowing through the specialty pharmacy channel. Going forward, we anticipate sustained momentum in AML throughout 2021, resulting in net sales somewhere between $160 million and $170 million for 2021. Now shifting to mitapivat and pyruvate kinase deficiency. Launch planning remains on schedule and has gained further momentum from the announcement of favorable ACTIVATE and ACTIVATE-T trial data. During the prior quarter, we shared news about the introduction of Anemia ID, our collaboration with PerkinElmer Genomics aimed at providing genetic testing at no cost for patients who may have hereditary anemias. This panel of 50 genes can assist in delivering a conclusive diagnosis of what's causing their anemia, and it forms a vital component of our multi-front strategy to speed up patient identification and disease education within the U.S. While COVID-19 keeps posing obstacles around commercial promotion, we've drawn several significant lessons from our AML sales and marketing experience that are shaping a more streamlined build for PK deficiency, covering things like sales force sizing and our marketing mix. Let me take this moment to convey my gratitude to the whole Agios oncology team for everything they've done all year, which stands out even more given the conditions we faced. Resilience, grit and steadfast dedication to patients form the foundation of this performance, and thousands of patients along with everyone at Agios appreciate it. I'll hand things over now to Jonathan for the Q4 financials.
Jonathan Biller
executiveThanks, Darrin. The financial results for our fourth quarter and all of 2020 are available in the press release that came out this morning, and I'll walk through the highlights. Our 10-K filing, which comes later today, will have more specifics. Revenue totaled $44 million in the fourth quarter, which brought the full year 2020 figure to $203.2 million — that's a gain of $85.3 million over 2019. As Jackie and Darrin noted, TIBSOVO product sales reached $39.1 million in Q4 and $121.1 million for the whole of 2020, up $61.2 million from 2019. Collaboration revenue came to $2 million in the fourth quarter and $71.8 million for full year 2020, which is $24.3 million more than 2019. That higher collaboration revenue for 2020 resulted from recognizing what remained of the deferred revenue balance tied to wrapping up the metabolic immuno-oncology collaboration with Celgene BMS. Also included in our 2020 revenue is $10.3 million of royalty revenue from IDHIFA's net global sales, with $2.9 million of that recorded in the fourth quarter. Keep in mind that we divested the IDHIFA royalty revenues to Royalty Pharma during Q2 2020, though under GAAP we still book that royalty revenue. Cost of sales was $1 million in the fourth quarter and $2.8 million for full year 2020. The $1.5 million year-over-year rise came from ex factory sales. Now to operating expenses. R&D came in at $95.7 million for Q4 and $367.5 million for full year 2020, which is $43.4 million lower than full year 2019. That year-over-year drop in R&D was mostly attributable to winding down the ClarIDHy study along with the Phase I study of TIBSOVO in hematologic malignancies, the deprioritization of AG-636, and reduced milestones incurred for HOVON. SG&A expenses totaled $39.8 million in the fourth quarter and $149.1 million for full year 2020; that's a $17 million rise versus full year 2019, mainly from greater workforce expenses in the U.S; and EU as well as professional fees connected to the Servier transaction. We closed the quarter with $670.5 million in cash, cash equivalents and marketable securities. We anticipate that this cash balance, along with expected product revenue, interest income and expense reimbursements under our collaboration agreements — though not counting any further program-specific milestone payments — will support our current operating plan through the end of 2022. Once the Servier transaction closes and after the planned capital return, Agios expects it can fund its operations through major catalysts and reach cash flow positivity without raising additional equity. Like we said before, our intention is to restructure the way our capital is set up so it matches what our company—focused on genetically defined disease—looks like, and that means giving back $1.2 billion in capital through buying back shares across a 12- to 18-month window once closing happens; details about how we'll handle the tactics and mechanics of those repurchases will come later; so with that, operator, could you please open up the line for questions.
Peter Lawson
analystRegarding sickle cell, I have a brief inquiry about the 100-milligram dose. What is the timeline for when additional data might become available? Also, do you consider that an essential piece for advancing in sickle cell?
Chris Bowden
executivePeter, this is Chris Bowden speaking. At this point, we aren't providing guidance on the Phase II portion of the study that I described in my prepared remarks. Once it's underway and we have a better understanding of accrual, we can share additional details. Definitely within the next year, additional data will emerge from the ongoing trials at the NIH as well as Utrecht, where we will be in a position to — we'll be presenting more — apologies, 100-milligram clinical data going forward.
Tyler Van Buren
analystMy question concerns the design of the sickle cell trial. If I recall correctly, the HOPE study for oxbryta, or voxelotor, only used a hemoglobin response rate as its primary endpoint, while this one has what amounts to 2 primary endpoints. Was adding the sickle cell pain crises endpoint something the FDA mainly demanded? Or did you folks decide to include it yourselves? And must you succeed on both of them to get approval? It would also help to understand this alongside the fact that you set the lower-bound cutoff for sickle cell pain crises over the past 12 months at 2 rather than 1. I was surprised to hear that 42% of patients in the HOPE trial had 1 crisis. So I imagine you expect that to strengthen the signal as well.
Chris Bowden
executiveYes. Tyler, this is Chris. You raised a number of different points. Voxelotor got accelerated approval based on the rise in hemoglobin. And as you know, and as all of us have been watching, they have not shown a statistically significant decrease in vaso-occlusive crisis. In our discussions with health authorities, VOCs, whether as a primary endpoint or a very highly ranked secondary endpoint, are essential when judging the therapeutic index, so to speak, and the clinical benefit of the molecule. For the specific trial we're proposing, with 2 primary endpoints, if we succeed on either 1, the study is positive. The interesting question then becomes how regulators view the clinical benefit from that trial. By structuring it this way, if we succeed on one, we have a positive trial. And we believe we're going to design the trial so that we have a compelling case for clinical benefit if we succeed on either endpoint. In the end, that depends on the data. And if you succeed on both, naturally, that's our best case scenario. And we believe mitapivat's mechanism of action supports our designing the trial and gives us some reason to believe that could happen. I think the main thing — one of the main things we want to convey, and this matches what we've said about pyruvate kinase deficiency, is that in a setting where — like sickle cell disease, where raising hemoglobin matters, you have to — have other supportive data alongside that. So connecting back to pyruvate kinase deficiency, we've heard for a long time, very consistently, that if you turn up with a hemoglobin increase that's statistically significant, but there's no other clinical data showing patients are feeling better and you're addressing hemolysis, then you're going to have a tough sell.
Anupam Rama
analystMy recollection is that we previously mentioned roughly 1,100 PKD patients who had been identified across the U.S. and key OUS territories. That figure was provided some time back, possibly during ASH 2019. So what does the patient count look like now? How did identification efforts progress during 2020? And what is our outlook for finding patients moving ahead?
Darrin Miles
executiveAnupam, Darrin speaking. You've got that right. Most recently — actually, during our latest webinar focused on the mitapivat program — we discussed this. Our updated figure was restated at approximately 1,000 patients. Because of COVID, spotting patients at the pace we'd have preferred became harder, since it requires interacting with doctors at different conference venues and in their clinics, that sort of thing. Even so, that tally keeps growing as time passes. We anticipate that growth will pick up speed throughout this year. Something I consider truly significant — and honestly somewhat unexpected on our end — is having a solid grasp of the full array of efforts or approaches we're using to speed up patient discovery, including the Anemia ID program, which we've mentioned before. I got a recent report on our status with that. By the time this quarter ends, we're on track to surpass the total number of tests sent out that we'd projected for all of 2021. Plus, the PKD positivity rate we're observing is close to what came out of the Spanish experience, or the Spanish IST, that we referenced earlier. So we think that will play a major role in driving our patient finding efforts this year, and it tells us that the urgency and enthusiasm surrounding this condition — and ideally mitapivat as well — is already beyond what we expected.
Jacqualyn Fouse
executiveYeah, and this is Jackie. I think, when you look past everything Darrin mentioned, plus what we've seen along the way with both the ACTIVATE and ACTIVATE-T data, and what we put out today — which I believe matters a great deal — the fact that we reached statistical significance on the key prespecified secondary endpoints for ACTIVATE, the PRO data included, makes for a really solid package. It lets us keep pushing forward with all the work Darrin and his team have underway, along with what our medical affairs folks are doing. And I think it will land as a very persuasive message, for physicians and for patients alike: look, this isn't only about efficacy data. We're also seeing — not hearing, seeing — in the PRO data from patients in this trial that there is benefit. So I'd say it's a pretty strong message.
Kennen MacKay
analystJackie, you really called it — what a year, and congratulations on closing it out with so much momentum. I wanted to ask about the mitapivat program in sickle cell disease. I'm curious — if you leave out patients who are either on voxelotor or crizanlizumab, or any of those other agents that alter hemoglobin oxygen affinity, it feels like enrollment, at least here in the U.S., might be somewhat difficult. So I'm wondering how that will affect getting patients into the trial compared with earlier studies, when nothing was on the market?
Chris Bowden
executiveYes. Kennen, this is Chris. I believe you've hit on one of the interesting issues we ran into — a fairly similar scenario in leukemia and AML with the IDH inhibitors, when we were entering with TIBSOVO and IDHIFA into a landscape that was shifting quickly. Some things you can anticipate and some you can't. Let's just take those drugs one at a time. Voxelotor — if we decided to allow it, then first you'd have to figure out whether there's a drug-drug interaction; and second, you'd likely have to design your trial somehow to include some kind of comparison. So being able to run a placebo-controlled study is an advantage in a way. But there will definitely be patients in the United States who are taking voxelotor, whose hemoglobin has risen. And from the perspective of their physician and the patient themselves, they'll be content. And there will also be people who might be on both drugs, crizanlizumab and voxelotor. So for sure, there will be a wave of shifts as patients — as new drugs reach patients. At the same time, there will be — sickle cell is a worldwide disease; so we're going to broaden our recruitment efforts, and that's a major piece of our feasibility. And Hydrea obviously will be permitted. It's a standard of care. A lot of patients take it. So I think that — and then if you consider the number of the substantial percentage of patients who don't respond to voxelotor, they'll be seeking another option, and joining this study will be an appealing one for them, we hope. So overall, I think, certainly, the arrival of new therapies is a positive thing for patients. They have more choices. At the same time, it also increases awareness in the community. None of these drugs work 100% of the time, and they certainly have gaps in their target product profile; we need to determine whether we can fill those gaps. But I think that, given the data we've produced so far and how attractive the mechanism of action is, we believe we have a good shot; and our early feasibility is showing us that people are very eager to talk with patients about joining the study.
Michael Schmidt
analystI had a follow-up for Chris regarding the trial design for sickle cell disease; it appears — sounds as though — a good deal of the FDA conversation might also have centered on picking the dose. And I was simply wondering whether you might elaborate a bit more on what their thinking involved when they requested that you examine both the 50- and the 100-milligram dose rather than just going with 100, the way you're doing it in the thalassemia study.
Chris Bowden
executiveRight. It's that 50 to 100 milligrams, where according to the data we've gathered thus far, an increase in the pharmacodynamic changes shows up; and you can't — right now, we believe we're quite near the maximal hemoglobin response at 50. Even so, in thalassemia, we felt as though we identified a handful more patients. What they told us, which aligns somewhat with EMA, is that this is a complex disease; they've witnessed many drugs fail. So we recommended that, and you'll assist us in grasping the risk-benefit of your drug and what you take into Phase III by conducting a Phase II investigation component and comprehending further how this pharmacodynamic 2,3-DPG ATP relationship, hemoglobin relationship and safety appear across these 2 doses before you decide to advance 1; and that was among the reasons behind it. And then they were quite explicit about some of that hemoglobin-related component that I mentioned regarding the trial design.
Mohit Bansal
analystJames here, filling in for Mohit. I'll keep this brief and focus on AG-946. To move ahead with the sickle cell disease cohort, what results from the SAD/MAD trial would you require? And on a somewhat connected note, I'm wondering whether 946 has an extended half-life and whether it could be given once a day.
Chris Bowden
executiveOn that second point, Chris Bowden here: once-a-day dosing is a possibility. As for what we'd need to observe before advancing it, it would have to get past the hurdles we'd anticipate — namely drops in 2, 3-DPG alongside rises in ATP, plus a safety profile that's adequate and a pharmacokinetic profile that's predictable and reasonable. That, essentially, is the full set of data we'd review. We'd also want the ability to observe or analyze those data across a number of separate cohorts, and dosing in those is currently underway.
Marc Frahm
analystCongratulations on the progress you've made with < > across the board. I'd like to build on a few of the earlier questions regarding the sickle cell trial design, Chris. Could you give us some detail on how the alpha is being divided across the co-primary endpoints? And tied to that, what power do you anticipate for the pain crises? Also, are there any stratification factors we ought to keep in mind, such as hydroxyurea use or the specific baseline rate of sickle crises?
Chris Bowden
executiveThose are a lot of good questions, Marc; this isn't a co-primary endpoint. What we have is 2 primary endpoints. If the trial succeeds on either of them, it's positive, and we'll be sharing more specifics about the trial's statistics at a later point, particularly once we have things up and running. Regarding your question about VOCs — what numbers we'd anticipate and how hydroxyurea factors in — I'd say that's among the most difficult things to forecast in this disease, and it's made even harder because you now have crizanlizumab, at least in the U.S. and expanding across Europe, a drug that works to lower how often VOCs occur. So that's something we'll need to monitor. That's part of why we structured the trial the way we did, so it can succeed based on either of those readouts, which is close to the best case, and we do have grounds to think we could bring VOCs down. And if you review the history of trials and look at — most recently, the voxelotor trial, which clearly improved hemoglobin yet couldn't show a reduction in VOCs — there's obviously an unmet need there. And there's — the other aspect of your question is that this disease has a great deal of heterogeneity; that's part of why we've gotten substantial input from both the EMA and the FDA as we've pulled all of this together. A trial design combines many elements; it's input from the authorities. It's conversations with people who have the disease, sickle cell in this instance, and they discuss problems with access. They discuss problems with trusting the medical community. When they describe their symptoms, the one that stands out most strongly is pain. So those are the kinds of things that go into pulling all of it together. So you get a combination of suggestions and mandates when regulators respond. As a result, a business needs to stake out certain positions, particularly while trying to reconcile the EMA with the FDA, since the guidance they provide typically contains a fair amount of contradiction. After that, you must consider how things look from the standpoint of operations and what can realistically be done. Bringing every one of those pieces together is enjoyable, difficult, and intricate. We've put in a lot of effort to arrive at the plan we now have, which in our view strikes a balance among all these considerations and maximizes our odds of running a successful study showing clinical benefit for people who have sickle cell disease.
John Newman
analystChris, I'm just wondering about the Phase II/III study in sickle cell disease — will you be able to examine any kind of PRO, or any measure of fatigue and so on, among patients? I realize this has historically been quite hard to do in sickle cell disease, but I'm just wondering whether you've built anything like that into the trial?
Chris Bowden
executiveJohn, patient-reported outcomes and quality of life are going to be a crucial component of this study. That traces back to the feedback we've received, going all the way to our early entry, I don't know how many years back, into pyruvate kinase deficiency. And those data — be it quality of life or patient-reported outcomes — matter greatly in the context of this trial. Really, they matter in every one of these trials, when hemoglobin elevation serves as your primary endpoint; yet you must be capable of showing that patients actually feel better. It offers some evidence that patients are feeling better, whether that comes through individual responders in your experimental arm. So yes, collecting those data is something we have to do. Demonstrating clinical benefit will depend heavily on it, in a trial that shows hemoglobin going up but misses on VOCs, since the trial could still read out positive. And then the regulators who govern approval will ask, "So what else can you show us proving that patients whose hemoglobin rises feel better?" After that, payers won't be posing that same question. So that represents a key element of the trial. And plenty of work has gone into attempting to characterize the burden of disease and to lessen that burden through drug therapy among patients with sickle cell disease. So there are validated scales, there's the 6-minute walk test, and there are numerous things one can examine. It's difficult, and we don't — we're entering this with our eyes wide open. As I said, many drugs that came out positive or marginally positive, or whatever you'd call it, failed to demonstrate those improvements. So this is a very challenging area, but it's absolutely essential.
Kalpit Patel
analystThis is Kalpit covering for Mark. And a fast question for Chris. Do you intend to put any titration or tapering plans in place for the Phase II/III sickle cell trial that's coming up?
Chris Bowden
executiveWhen it comes to mitapivat, we will — given that we entered pyruvate kinase deficiency, our thinking is — we advise tapering this drug. Abrupt discontinuation is not something we advise. So that aspect stays the same. As for the Phase II part, patients will simply begin at 50 and 100 milligrams; no upward titration will occur.
Chris Liu
analystThis is Chris, filling in for Andy. I realize you mentioned that additional details regarding the planned share buybacks will come at a later point. However, I was simply curious whether there might be any assistance or insight on the broader elements of it, for example, do you anticipate beginning immediately once the process wraps up? Or and would it happen through the market or possibly a tender?
Jonathan Biller
executiveJonathan here. Appreciate the question. What your question implies is that there are numerous approaches for carrying out share repurchases; relative to our market cap, we have a rather substantial volume of repurchases to complete. Therefore, I believe it's reasonable to state you could and we've indicated that we'll carry it out across 12 to 18 months. Thus, I think it's reasonable to anticipate that there will probably be more than 1 method through which we'll accomplish it. Our planning at present is in progress, and it's genuinely intended to attempt to guarantee that we complete it in the most efficient manner we can and in the manner most likely to boost long-term shareholder value. We'll offer additional guidance as we move nearer to executing and we would anticipate that we will be starting share repurchases at some point in due course after closing, but more to come on that.
Jacqualyn Fouse
executiveI appreciate it, operator, and I'm grateful to each of you for being here this morning. We're eager to have more exchanges with you in the weeks and months ahead. Let me just say again that even with the difficulties and unknowns in front of us, I continue to feel a great deal of enthusiasm about how much headway we're making in our focus areas during this year, and also about what our team has accomplished in our oncology programs. As a final note, I want to express a lot of gratitude to my Agios colleagues for the commitment and the passion they bring to changing things for our patients, in oncology as well as in genetically defined diseases. My thanks go out as well to every patient, caregiver and physician involved in our clinical trials — absent them, we couldn't do what we do. Thanks once more for being with us today. Take care.
Operator
operatorThat wraps up today's call, everyone. We appreciate your participation, and you're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.